Study 6 of 6Teduglutide literaturebiorxiv-preprint · Meta-analysis

Impact of Teduglutide on Pediatric Short Bowel Syndrome: Protocol for a Systematic Review and Trial Sequential Meta-Analysis

Not reported in abstract.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the teduglutide corpus

Preclinical

Observational

Open-label

Randomised

Reviews · this one

Summary and findings

This systematic review and meta-analysis aims to evaluate the efficacy and safety of teduglutide in pediatric patients with short bowel syndrome. It will include randomized controlled trials and cohort studies comparing teduglutide to placebo or standard treatments. The findings are intended to provide evidence for clinical practitioners and families.

How much of this paper we could read: title only (0.30). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →

Not reported in abstract.

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Background</bold> Although studies have evaluated the safety and efficacy of GLP drugs in adult patients with short bowel syndrome, pediatric applications remain contentious due to developmental divergences in drug response and safety profiles. This meta-analysis aims at systematically evaluating efficacy and safety outcomes of teduglutide in pediatric SBS and providing comprehensive evidence for clinical practitioners and families of affected children. <bold>Methods and analysis:</bold> Randomized controlled trials (RCTs) and cohort studies comparing teduglutide and placebo or regular treatments in pediatric patients with a confirmed diagnosis of short bowel syndrome will be included. Literature searches will be conducted in PubMed, Web of Science, Embase, and Cochrane Library. Two reviewers independently perform the processes of literature retrieval, screening, data extraction, and assessment of risk of bias. Risk of bias in included studies is evaluated using Revised Cochrane risk-of-bias tool (ROB 2) for RCTs and Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-1) for non-RCTs. Review Manager (RevMan) was used for data pooling. Subgroup analysis, meta-regression, trial sequential analysis (TSA), and sensitivity analysis are conducted. <bold>Ethics and dissemination:</bold> Ethical approval is not required because this study is a secondary analysis of existing data. We will disseminate the findings through peer- reviewed publications. <bold>PROSPERO registration number:</bold> CRD420251047221 </p>

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Teduglutide corpus

BTeduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Reportbiorxiv-preprint · Not reported in abstract.Human CGLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.Nature metabolism · 2025 · Not reported in abstract.Animal BPersonalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.The Journal of clinical endocrinology and metabolism · 2026 · Not reported in abstract.Human BSuccessful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review.International journal of surgery case reports · 2026 · Stool frequency decreased to 3-5 times per day after 4 months of teduglutide treatment.Human BSafety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.Pediatric research · 2026 · Mean percent reduction in parenteral calories was 49.5% by 3 years.Human